Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 vs Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06629597Phase 3Active, not recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of YL201 in nasopharyngeal carcinoma (NPC), sponsored by MediLink Therapeutics. Started Dec 2024; status: active, not recruiting.
02
Drugs
YL201
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06629597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629597.